Abstract
In this issue, Van der Heijde and colleagues1 report the results of a randomised, prospective, placebo-controlled, dose-ranging trial evaluating the short-term (12 weeks) symptomatic effect of a Janus kinase (JAK)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have